Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient : a case report
An 81-year-old man on chronic hemodialysis was referred to our hospital with urinary difficulty. Transperineal needle biopsy of a hard nodule in the prostate revealed moderately differentiated adenocarcinoma. He was diagnosed to have stage C prostate cancer. A standard dose of luteinizing hormone-re...
| Publié dans: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 43(1997), 6 vom: 04. Juni, Seite 421-3 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , |
| Format: | Article |
| Langue: | Japanese |
| Publié: |
1997
|
| Accès à la collection: | Hinyokika kiyo. Acta urologica Japonica |
| Sujets: | Case Reports English Abstract Journal Article Antineoplastic Agents, Hormonal Testosterone 3XMK78S47O Luteinizing Hormone 9002-67-9 Leuprolide EFY6W0M8TG |
| Résumé: | An 81-year-old man on chronic hemodialysis was referred to our hospital with urinary difficulty. Transperineal needle biopsy of a hard nodule in the prostate revealed moderately differentiated adenocarcinoma. He was diagnosed to have stage C prostate cancer. A standard dose of luteinizing hormone-releasing hormone (LH-RH) analogue, leuprorelin acetate (3.75 mg), was administered every 4 weeks for 15 months. No adverse effects were observed throughout the period. The clinical response to LH-RH analogue was excellent, with normalization of serum prostate-specific antigen level and relief of dysuria. Thus the standard dosage of LH-RH analogue is considered to be adequate for hemodialysis patients |
|---|---|
| Description: | Date Completed 15.09.1997 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |